Literature DB >> 16309177

Preclinical studies of the novel vascular disrupting agent MN-029.

Wenyin Shi1, Dietmar W Siemann.   

Abstract

BACKGROUND: Vascular disrupting agents (VDAs) are designed to cause a rapid and selective shutdown of the established tumor vasculature, which leads to secondary ischemic tumor cell death.
MATERIALS AND METHODS: We examined the efficacy of a novel VDA, MN-029, in the rodent KHT sarcoma model.
RESULTS: A significant reduction in the functional vessel number was observed after intraperitoneal injection of MN-029 at a dose of 100 mg/kg. Histological evaluation showed extensive necrosis (approximately 90%) by 24 h. MN-029 treatment to the tumor-bearing mice also resulted in a dose-dependent tumor cell killing. When used in combination with radiation or cisplatin chemotherapy, a 100 mg/kg dose of MN-029 significantly enhanced tumor killing compared to that seen with radiation or cisplatin alone.
CONCLUSION: The results demonstrated that MN-029 could cause rapid vascular shutdown in solid tumors, dose-dependent secondary tumor cell killing, and effective enhancement of the antitumor effects of radiation and cisplatin chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16309177

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.

Authors:  Chryso Kanthou; Gillian M Tozer
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

Review 2.  An overview of tubulin inhibitors that interact with the colchicine binding site.

Authors:  Yan Lu; Jianjun Chen; Min Xiao; Wei Li; Duane D Miller
Journal:  Pharm Res       Date:  2012-07-20       Impact factor: 4.200

Review 3.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Authors:  Dietmar W Siemann
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

4.  Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases.

Authors:  Roben G Gieling; Richard J Fitzmaurice; Brian A Telfer; Muhammad Babur; Kaye J Williams
Journal:  Clin Exp Metastasis       Date:  2015-06-26       Impact factor: 5.150

5.  Synthesis and biological evaluation of 2-aryl-benzimidazole derivatives of dehydroabietic acid as novel tubulin polymerization inhibitors.

Authors:  Ting-Ting Miao; Xu-Bing Tao; Dong-Dong Li; Hao Chen; Xiao-Yan Jin; Yi Geng; Shi-Fa Wang; Wen Gu
Journal:  RSC Adv       Date:  2018-05-16       Impact factor: 4.036

6.  A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors.

Authors:  Anne M Traynor; Michael S Gordon; Dona Alberti; David S Mendelson; Mark S Munsey; George Wilding; Richard E Gammans; William L Read
Journal:  Invest New Drugs       Date:  2009-05-13       Impact factor: 3.850

7.  Radiotherapy in combination with vascular-targeted therapies.

Authors:  Eva Ciric; Gregor Sersa
Journal:  Radiol Oncol       Date:  2010-05-24       Impact factor: 2.991

Review 8.  Vascular disrupting agents in clinical development.

Authors:  P Hinnen; F A L M Eskens
Journal:  Br J Cancer       Date:  2007-03-20       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.